Takeda exits cell therapy research

Takeda will seek an external partner to leverage its cell therapy platform technologies

Takeda announced that as part of a strategic portfolio prioritization process, the company has made the decision to discontinue its cell therapy efforts.

Takeda will seek an external partner to leverage its cell therapy platform technologies and to further advance the company’s research and clinic-ready programs in this field. The company has no current active clinical trials utilizing cell therapy technology.

Takeda will refocus near-term investments into programs that it believes can deliver transformative therapies to patients at increased speed and scale.

The company’s preclinical programs utilizing its in-focus modalities, including small molecules, biologics, and antibody-drug conjugates, are advancing novel and highly innovative therapeutic candidates.

Takeda’s preclinical research programs will continue to benefit from the novel insights gained from its cell therapy research.